News and Trends 13 Oct 2016
Adaptimmune Revises TCR Protocol following Phase I/IIa Failure
Shares of Adaptimmune slid 12% yesterday morning after the company updated its TCR therapy to include fludarabine, which was linked to deaths in Juno's CAR-T trials. Despite optimism that T-cells…